Journal profile · Medicine-Oncology
Leukemia Research Reports
ISSN 2213-0489 · Elsevier · Netherlands
Leukemia Research Reports: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.8 (journal website); fully open access; APC about USD 1,390; median 120 days to acceptance (98 articles, last 24 months); 60 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Leukemia Research Reports is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments and Chronic Lymphocytic Leukemia Research, together about 39.9% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Official journal of the Myelodysplastic Syndromes Foundation.Leukemia Research Reports (LRR), a companion title to Leukemia Research, is a peer-reviewed publication devoted to the rapid publication of short, high-quality papers related to a broad scope of therapeutic areas of hematology, including hematologic malignancies and other non-malignant diseases, such as:Hematopoetic and stem cell transplantation;Marrow and stem cell reconstitution;Leukemic hemopoiesis;Leukemias, lymphomas, multiple myelomas and other hematological malignancies;Cell based therapies and treatment for cancer and immunotherapy for hematological malignancy.The journal aims to publish manuscripts that provide guidance to clinicians around the world to provide education on best practices and clinical research; report cutting-edge translational science related to hematological malignancies; register important observations that significantly add to previously-reported novel observations; provide compelling illustrations of important clinical principles related to the care of patients; or foment the scientific discussion from an uncommon perspective.All articles published in Leukemia Research Reports are peer-reviewed and indexed in PubMed/PubMed Central and Scopus. They are fully citable through digital object identifiers (DOI) and rapidly available online via ScienceDirect, the world's leading online content platform.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Luis F. PorrataPublisher website
Editorial board by country: none in mainland China; most named United States 12, Canada 3, Chile 3, United Kingdom 2, Japan 1 (25 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine20.6%
- Chronic Myeloid Leukemia TreatmentsMedicine10.1%
- Chronic Lymphocytic Leukemia ResearchMedicine9.2%
- Lymphoma Diagnosis and TreatmentMedicine8.1%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine7.1%
- Acute Lymphoblastic Leukemia researchMedicine6.7%
- Multiple Myeloma Research and TreatmentsMedicine4.9%
- Eosinophilic Disorders and SyndromesMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 0.8Publisher website ·
- CiteScore 2026-06
- 1.6LetPub ·
- CiteScore (publisher)
- 1.6Publisher website ·
- SJR 2026-06
- 0.33LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 21OpenAlex ·
- i10-index
- 81OpenAlex ·
- 2-year mean citedness
- 0.47OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 48LetPub ·
Articles by year OpenAlex count · 598 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 52 | 52 | 6 |
| 2025 | 60 | 60 | 28 |
| 2024 | 84 | 84 | 58 |
| 2023 | 48 | 48 | 94 |
| 2022 | 68 | 68 | 270 |
| 2021 | 55 | 55 | 246 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
120 daysMedian, submission to acceptance · P25–P75 69 days – 177 days
- Acceptance to online
- median 1 days (98 articles)
- Submission to online
- median 124 days
- Sample
- 98 articles with submission and acceptance dates (117 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 23 weeksLetPub ·
- Submission to first decision
- 36 daysPublisher website ·
- First decision after review
- 59 daysPublisher website ·
- Submission to acceptance
- 101 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,390 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 1,180 / EUR 1,100 / GBP 940 / JPY 146,360 | — | — | |
| LetPub | USD 880 | Yes | — | |
| Publisher website | USD 1,740 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 3,500 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
Article types accepted8, with length limits
- case reportWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…main text ≤ 1,500 words · abstract ≤ 500 words · references ≤ 10
- commentaryWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…Length not stated
- letterWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…Length not stated
- perspectiveWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…main text ≤ 1,500 words · references ≤ 10
- research reportWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…Length not stated
- reviewWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…Length not stated
- short research communicationsShort Research CommunicationsPapers that present original and significant material for rapid dissemination, that may be a preliminary report of work completed, …Length not stated
- viewpointWord count limit does not include the references, acknowledgement document, figures and tables.Short Research CommunicationsPapers that present original and sig…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2213-0489
- Society / sponsor
- Myelodysplastic Syndromes Foundation
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Leukemia Research Reports
What CAS zone is Leukemia Research Reports in?
In the 2025 upgraded edition of the CAS Journal Ranking, Leukemia Research Reports is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Leukemia Research Reports?
The journal's website gives an impact factor of 0.8; this is the journal's own figure, as LetPub lists none for it; CiteScore 1.6, h-index 21.
How long does peer review take at Leukemia Research Reports?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 120 days (interquartile range 69–177 days); authors report an average review time of about 23 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Leukemia Research Reports?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 3,500 words; Reference style: Numbered, in order of citation; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Leukemia Research Reports based?
Of the 25 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (12), Canada (3) and Chile (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Leukemia Research Reports?
According to LetPub and DOAJ records, Leukemia Research Reports is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Leukemia Research Reports open access, and what is the APC?
Leukemia Research Reports is a fully open-access journal. APC about USD 1,390.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .